Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Curis Inc (CRIS)

Curis Inc (CRIS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 1, 2019, the independent Compensation...

CRIS : 2.08 (+0.48%)
Patients Turn to Assistance Programs for Aid in the Fight Against Chronic Diseases

With the advancement of the cancer therapy market, new forms of treatment are now being studied and manufactured. Additionally, demand is expected to keep growing for currently effective treatments. Not...

CRIS : 2.08 (+0.48%)
IMMU : 14.17 (+1.29%)
ZIOP : 4.24 (+0.47%)
ONPH : 0.0400 (-3.38%)
Curis to Present at Cantor Fitzgerald Global Healthcare Conference

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, Chief Executive Officer of Curis,...

CRIS : 2.08 (+0.48%)
Curis Announces Promotion of Bill Steinkrauss to Chief Financial Officer

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the promotion of Bill Steinkrauss to Chief Financial...

CRIS : 2.08 (+0.48%)
Curis Hires Industry Veterans to Lead Clinical Development and Regulatory Affairs

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of Reinhard von Roemeling, M.D., as...

CRIS : 2.08 (+0.48%)
Curis: 2Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $7.2 million in its second quarter.

CRIS : 2.08 (+0.48%)
Curis Reports Second Quarter 2019 Financial Results

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the second quarter ended...

CRIS : 2.08 (+0.48%)
Curis to Release Second Quarter Financial Results and Hold Conference Call on August 6, 2019

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its second quarter financial...

CRIS : 2.08 (+0.48%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on July 1, 2019, the independent Compensation...

CRIS : 2.08 (+0.48%)
Curis: 1Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $9.9 million in its first quarter.

CRIS : 2.08 (+0.48%)
Curis Reports First Quarter 2019 Financial Results

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the first quarter ended March...

CRIS : 2.08 (+0.48%)
Curis to Release First Quarter Financial Results and Hold Conference Call on May 14, 2019

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its first quarter financial...

CRIS : 2.08 (+0.48%)
Curis Completes Mesothelioma Enrollment in CA-170 Study

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Phase 1 study of CA-170 has reached its target...

CRIS : 2.08 (+0.48%)
Healthcare Companies Search for New Ways to Oppose the Spread of Cancer

Cancer is among one of the leading causes of death in the world since many countries are burdened by the lack of access to adequate healthcare, which results in the high number of deaths. In 2018, the...

SNETD : 0.3900 (+14.71%)
SNET : 0.0103 (+63.49%)
CVM : 8.26 (-1.43%)
CRIS : 2.08 (+0.48%)
GERN : 1.53 (+6.25%)
NLNK : 1.17 (unch)
Research Report Identifies Denison Mine, Obsidian Energy, Cherry Hill Mortgage Investment, Curis, DASAN Zhone Solutions, and CVD Equipment with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Denison Mine Corp (NYSE:DNN), Obsidian...

DNN : 0.48 (-1.67%)
OBE : 0.67 (+3.92%)
CHMI : 12.93 (+0.47%)
CRIS : 2.08 (+0.48%)
DZSI : 7.09 (+0.14%)
CVV : 3.11 (-0.32%)
Curis Regains Compliance with Nasdaq Continued Listing Requirements

Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it received written confirmation from the Listing...

CRIS : 2.08 (+0.48%)
Curis Announces Advancement to the 200mg BID Cohort in the CA-4948 Study

Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, announced today that it has begun dosing patients in the 5th cohort...

CRIS : 2.08 (+0.48%)
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April 2, 2019, the independent Compensation...

CRIS : 2.08 (+0.48%)
Curis: 4Q Earnings Snapshot

LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Tuesday reported a loss of $5.9 million in its fourth quarter.

CRIS : 2.08 (+0.48%)
Curis Reports Fourth Quarter and Year-End 2018 Financial Results

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today reported its financial results for the fourth quarter and year...

CRIS : 2.08 (+0.48%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI -1.54 , AIZ +0.24 , SBAC -1.35 , SO -0.28 , WELL -0.42
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar